Compact Design, Big Impact: Tridek-One Therapeutics Leverages MyGlo® to Accelerate Discovery of Immunomodulating Treatments

Posted on by Promega

In today’s biotech landscape, speed and precision are essential. For Tridek-One Therapeutics, a Paris-based spin-off from INSERM founded in 2018, these qualities drive their mission to develop first-in-class CD31 checkpoint agonist therapies for autoimmune and inflammatory diseases. By leveraging CD31’s ITIM motifs to modulate ITAM signaling, their approach targets immune cells selectively, reducing the risk of broad immunosuppression.

Operating in a biotech incubator with limited space and shared equipment, the team—including Trang Tran, PhD, Preclinical Research Director, and Guillaume Even, Senior Laboratory Technician—depends on luminescent assays requiring both sensitivity and precise timing. Relying on a shared plate reader often delayed extracellular ATP assays that needed rapid measurement. Walking between lab spaces and potentially waiting for access to the plate reader was not feasible.

Tridek-One needed a dedicated, reliable luminometer that could support their time-sensitive workflow and fit into their small lab space. That’s when Tridek-One discovered the MyGlo® Reagent Reader, Promega’s compact, portable 96-well luminometer and transformed their workflow. Even noted that, when they first tried MyGlo®, they “directly saw the power of this small machine.” Tran and Even found that MyGlo®’s performance and sensitivity were comparable to more expensive multi-mode readers, which gave them confidence in choosing MyGlo® as a reliable and cost-effective solution. Because they prefer to use 96-well microplates, MyGlo® fit their experimental setup perfectly.

Continue reading “Compact Design, Big Impact: Tridek-One Therapeutics Leverages MyGlo® to Accelerate Discovery of Immunomodulating Treatments”

Top 5 Luciferase Reporter Vectors You Didn’t Know You Needed (But Now Can’t Live Without) 

Posted on by Simon Moe

Ever spent your Friday night troubleshooting a cloning reaction that just won’t work? 

We’ve been there. So have thousands of other scientists. That’s why Promega and Addgene teamed up to create something game-changing: a curated collection of 600+ luciferase reporter vectors, designed to help you skip the cloning and get straight to the data. 

Addgene, the nonprofit plasmid-sharing platform trusted by researchers worldwide, and Promega, a global leader in luminescent assay technologies, have joined forces to make your gene expression, pathway analysis, and cell signaling experiments faster, easier, and reproducible. 

In this post, we’re spotlighting 5 standout vectors from the new collection that are making life in the lab a whole lot better. 

Continue reading “Top 5 Luciferase Reporter Vectors You Didn’t Know You Needed (But Now Can’t Live Without) “

Do Mosquitoes Have a Taste for Beer?

Posted on by Shannon Sindermann

Festival season is here—and apparently, mosquitoes got tickets too.

If you have ever been the person in your friend group who ends a summer concert covered in large, itchy welts while everyone else goes home bite-free, you are not imagining things. Some people really are mosquito magnets.

Mosquito bite

A new study, aptly titled “Blood, Sweat, and Beers,” set out to uncover what makes certain humans irresistible to mosquitoes. But instead of a sterile lab or a rainforest expedition, this experiment took place at one of the Netherlands’ biggest music festivals; Lowlands, a three-day party with 65,000 attendees, questionable hygiene and plenty of beer. In other words: the perfect breeding ground for this science experiment.

Continue reading “Do Mosquitoes Have a Taste for Beer?”

One Health in Action: Integrated Solutions for Animal Health Pathogens

Posted on by Promega

For research use only

Introduction: Diagnostic Innovation for Zoonotic Threats

When a veterinarian detects influenza A in pigs, they’re not just protecting a herd; they’re helping safeguard public health through broad ongoing surveillance.

To support rapid, biosafe detection of Influenza A viruses (H5N1, H3N2, H1N1) in animal populations, Promega and Longhorn Vaccines and Diagnostics have partnered to create a workflow that doesn’t require BSL-3 containment. It’s scalable, field-ready, and designed with One Health in mind.

This work is part of our broader commitment to enabling real-time disease surveillance—across species and borders. Together with Longhorn, we’re building molecular diagnostics that meet the moment, and the future.

Want the technical details? Read the press release. 

Why It Matters: Influenza A and Diagnostic Bottlenecks

Influenza A viruses—including highly pathogenic strains like H5N1—pose a dual threat to animal health and human safety. Yet despite the urgency, many surveillance and research efforts stall at the lab bench. Why? Because working with zoonotic pathogens often requires high-containment (BSL-3) facilities—especially when dealing with real-world samples like cow milk, poultry swabs, or pig oral fluids.

To help overcome this barrier, Promega and Longhorn set out to design a complete diagnostic workflow that does more than just detect. It needed to:

Continue reading “One Health in Action: Integrated Solutions for Animal Health Pathogens”

What Drives Muscle Fiber Shifts in Obesity and Type ll Diabetes?

Posted on by Kari Kenefick

Skeletal muscle is the body’s main consumer of glucose derived from food.

Muscle Fiber Types
Skeletal muscle is composed of two types of muscle fiber: Type I (slow-twitch) and Type II (fast-twitch).
Type I fibers contract slowly and can maintain contraction over long periods of time. They are rich in mitochondria and myoglobin and are well vascularized. These fibers rely mostly on aerobic metabolism to make the ATP that fuels cells. Type I muscle fibers are fatigue-resistant and efficient—great for supporting posture, distance running, cycling and any activity that needs steady output.

Type II fibers contract quickly, produce more force and power, but also fatigue more quickly. They have fewer mitochondria and less vasculature and rely more on anaerobic pathways like glycolysis (using glucose without oxygen).

Type I muscle fibers are smaller in diameter and generate less peak force but excel at endurance and heat management. Type II fibers are typically larger, produce more force and speed and handle explosive tasks like sprinting, jumping or heavy lifting.

Most muscles are a mix of fiber types, and genetics sets the starting ratio of Type l to Type ll, but fibers are adaptable. With aging and disuse, Type II fibers tend to atrophy more, which is one reason that power declines faster than endurance.

Another distinction important for this story: Type I fibers are more insulin-sensitive than Type II fibers. Additionally, these fiber types differ in different body types.

Continue reading “What Drives Muscle Fiber Shifts in Obesity and Type ll Diabetes?”

Measure Engagement to Target Proteins within Complexes: Why Context Matters

Posted on by Promega

This blog was written by guest contributor Tian Yang, Associate Product Manager, Promega, in collaboration with Kristin Huwiler, Manager, Small Molecule Drug Discovery, Promega.

For target-based drug discovery programs, biochemical assays using purified target proteins are often run for initial hit discovery, as these assays are target-specific, quantitative and amenable for high-throughput screens, allowing for precise characterization of target-compound interactions. However, proteins do not act in isolation inside the cells. Instead, proteins form complexes with other cellular components to drive cellular processes, signaling cascades, and metabolic pathways. Just as the interactions between a target protein and its binding partners can influence the target function, compound engagement with target proteins can vary depending on the protein complex formed.

Continue reading “Measure Engagement to Target Proteins within Complexes: Why Context Matters”

What Shelter Dogs Can Tell Us About Emerging Zoonotic Diseases

Posted on by Michele Arduengo, PhD

Why Are Zoonotic Diseases Becoming a Bigger Risk?

As of September 9, 2025, the Worldometer listed the human global population as 8.3 billion people (1). This population growth means that humans will be living and working in previously uninhabited or minimally disturbed environments, increasing interactions between humans, domestic animals, wildlife, and their pathogens. This intensifying human-animal interface heightens the risk of zoonotic disease transmission, where pathogens cross species barriers (from wildlife to domestic livestock or from wildlife to humans), potentially leading to outbreaks and even pandemics.

How Do Urbanization and Climate Change Amplify Zoonotic Threats?

Urbanization, habitat disruption, and climate change further exacerbate these risks by altering ecosystems and facilitating the spread and emergence of vector-borne and zoonotic diseases. Understanding and addressing these threats requires robust surveillance, effective diagnostics, and proactive strategies to prevent and mitigate disease emergence and spread.

In urban areas, public health officials are already using wastewater to monitor known pathogens and identify “hot spots” of activity to predict increases in illness within local populations (2). Animal shelters are another place where there is an opportunity to monitor for emerging infectious diseases that could affect domestic pet animals.

Continue reading “What Shelter Dogs Can Tell Us About Emerging Zoonotic Diseases”

Polyserine Targeting: A New Strategy Against Neurodegeneration

Posted on by Johanna Lee

Neurodegenerative diseases like Alzheimer’s are marked by the accumulation of misfolded proteins that wreak havoc on neurons. One of the most notorious culprits is tau, a structural protein that, in its diseased form, clumps together into aggregates that spread throughout the brain. These aggregates interfere with normal cellular processes, leading to memory loss, behavioral changes, and other devastating symptoms. Preventing tau aggregation is therefore a key strategy for slowing the progression of these symptoms.

What if we could recruit molecular “helpers” to stop tau from accumulating?

Continue reading “Polyserine Targeting: A New Strategy Against Neurodegeneration”

A New View of Protein Degradation with HiBiT and Live Cell Imaging

Posted on by Anna Bennett

Targeted protein degradation (TPD) is an emerging drug discovery strategy that offers an entirely different approach to tackle disease-relevant proteins, including classic “undruggable” targets. Instead of inhibiting protein function, small molecules like PROTACs and molecular glues co-opt the cell’s own ubiquitin-proteasome system to eliminate specific proteins altogether. But as this targeted approach gains traction, it also challenges existing methods for validating compound activity.  

How do you confirm that degradation is happening in a biologically-relevant system? Can you validate protein degradation in real-time?  

Continue reading “A New View of Protein Degradation with HiBiT and Live Cell Imaging”

Exploring How NEAT1 Shapes Granulosa Cell Function

Posted on by Shannon Sindermann
Granulosa Cells

Granulosa cells (GCs), which surround and support developing oocytes, play a critical role in estrogen production, follicle maturation and overall ovarian health (3). Their ability to regulate hormone production and cell survival makes them a central focus in studies of ovarian biology.

A recent study investigated how the long non-coding RNA (lncRNA) NEAT1 regulates GC function and mapped a pathway that links NEAT1 expression to cell proliferation, apoptosis and hormone production (1).

Continue reading “Exploring How NEAT1 Shapes Granulosa Cell Function”